(DGX) News: Contact Leading Law Firm Johnson Fistel Regarding Investigation
SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP (www.JohnsonFistel.com) is investigating whether Quest Diagnostics Incorporated (“Quest” or the “Company”) (NYSE: DGX), any of its executive officers, or others violated federal securities laws by misrepresenting or failing to timely disclose material, adverse information to investors.
What actions may I take at this time? If you purchased Torrid securities and suffered significant losses on your investment, contact Johnson Fistel, LLP to submit your losses:
- Contact Lead Securities Analyst Jim Baker at [email protected] or (619) 814-4471
- Click [here] or paste the following web address into your browser to join the investigation:
https://www.cognitoforms.com/JohnsonFistel/QuestDiagnosticsIncorporated2
For more information, visit our website at https://www.johnsonfistel.com/faq
There is no cost or obligation to you.
What if I have information relevant to the investigation? Individuals with nonpublic information regarding Torrid should consider whether to assist our investigation or take advantage of the SEC Whistleblower program. Under the SEC program, whistleblowers who provide original information may, under certain circumstances, receive rewards totaling up to thirty percent of any successful recovery made by the SEC. For more information, contact Jim Baker at (619) 814-4471 or [email protected].
What is Johnson Fistel investigating? On January 1, 2022, New York Times released an article regarding the efficacy of Quest and other screening labs for certain prenatal tests. The article states that these tests produce misleading results and do not correctly disclose the chances of a false positive. The article elaborates stating, “The test is advertised as getting positive microdeletion results right 75 percent of the time. But that figure comes from a single study that included nine confirmed cases of microdeletions, for a test that screens for seven such disorders. The company doesn’t specify how the tests perform individually, and declined to provide that data. (In a statement, Quest said its test has “excellent performance.”).
Disclaimer: At this time, Johnson Fistel has not concluded whether any violations of law may have occurred or whether investors have valid legal claims for recovery of their losses.
About Johnson Fistel, LLP. Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in securities class action and derivative lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Follow us on Twitter: https://twitter.com/JF_LLP
Contact:
Johnson Fistel, LLP
Jim Baker, Lead Securities Analyst
Telephone: (619) 814-4471
Email: [email protected]
Disclaimer: This content is distributed by The GlobeNewswire
